Alzheimer's disease neuroimaging initiative 2 (ADNI2)
Steven G. Potkin, MD
UC Irvine Medical Center and the UC Irvine Brain Imaging Center for the PET scan portion of the study
The main purpose of this study is to look at the usefulness of imaging studies and biomarker tests, together with measurements of memory, thinking and daily functioning, in the future conduct of studies that will focus on the identification and treatment of Alzheimer's disease at an early stage. This study aims to produce data to be stored for these kinds of future research studies.
You are eligible to participate in this study if you are 55 to 90 years of age and have a study partner who you have frequent contact with (an average of 10 hours per week or more) who is willing to accompany you to all of the study visits who will communicate changes in your health to the study staff over the period of this study. You must also be willing to undergo all study procedures including repeated MRIs (no contraindications i.e. metal in your body or claustrophobia), PET scans, and lumbar puncture and agree to the collection of blood samples for banking and testing. Women must be two years post-menopausal or surgically sterile to be eligible. This study aims to enroll subjects, who are cognitively normal, have early mild cognitive impairment, late mild cognitive impairment, and Alzheimer's disease. Assessments will be done to determine which study group you qualify for.
Participants may involve up to 8 study visits as well as telephone contacts over the next 54 months. Additional visits will be required for the MRI and/or PET procedures.
There is no guarantee that you will personally benefit by participating in this research study. This study will not make your health better. Study procedures will be provided at no cost to you.
Total compensation for completing the study as an Alzheimer's disease (AD) subject is $1550 over the 54 month study period. Total compensation for completing the study as a cognitively normal, late mild cognitive impairment, or early mild cognitive impairment subject is $2250 over the 54 month study period. AD subjects have less study procedures and visits than the other study groups so their compensation is less.
Richard Jones, Department of Psychiatry and Human Behavior